系统性恶性肿瘤合并缺血性卒中患者的短期结局
研究回顾性分析468例系统性恶性肿瘤合并缺血性卒中患者,分为非活动性癌症、活动性非转移性癌症和转移性癌症三组,比较基线特征与6个月生存率。随访期间26.1%患者死亡,转移性癌症组6个月死亡率达67.1%。多因素Cox回归显示转移是6个月死亡的独立相关因素(HR 4.527,95%CI 2.175-9.422),而活动性非转移性癌症组与 非活动性癌症组的6个月死亡率相似(HR 0.711,95%CI 0.282-1.795)。胃癌/食管癌和胰腺癌亦与6个月死亡率独立相关。
要点
- 转移性癌症是缺血性卒中合并恶性肿瘤患者6个月死亡的独立危险因素。
- 活动性非转移性癌症患者6个月死亡率与非活动性癌症患者相似。
- 胃癌/食管癌和胰腺癌与6个月死亡率独立相关。
核心结论
- 在活动性癌症的卒中患者中,存在转移和癌症类型是与6个月死亡率相关的关键因素。
研究设计与样本
- 回顾性分析连续入组的系统性恶性肿瘤合并缺血性卒中患者,共468例,为期8年,分为非活动性癌症组223例、活动性非转移性癌症组105例和转移性癌症组140例。
主要发现
- 6个月随访期间共122例(26.1%)死亡,非活动性癌症组7.2%(16/223),活动性非转移性癌症组11.4%(12/105),转移性癌症组67.1%(94/140)。
- 多因素Cox回归显示转移与6个月死亡率独立相关(HR 4.527,95%CI 2.175-9.422)。
- 活动性非转移性癌症组与 非活动性癌症组的6个月死亡率相似(HR 0.711,95%CI 0.282-1.795)。
- 胃癌/食管癌和胰腺癌亦与6个月死亡率独立相关(HR分别为2.068和2.389)。
临床怎么用
- 对于合并活动性癌症的缺血性卒中患者,评估是否存在转移及癌症类型有助于判断6个月生存预期,可辅助静脉溶栓等治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Recent guidelines have suggested the potential benefit of intravenous thrombolysis in stroke patients with systemic malignancy who have a reasonable life expectancy of >6 months. However, it is difficult to determine which patients with cancer will have a life expectancy of >6 months. Therefore, we identified the factors associated with 6-month mortality in patients with acute ischemic stroke and systemic malignancy. Methods- Consecutive stroke patients with systemic malignancy were retrospectively analyzed. We classified the patients into 3 groups: the nonactive cancer, active nonmetastatic cancer, and metastatic cancer groups. We compared the baseline characteristics and 6-month survival rates. Results- Of the 468 ischemic stroke patients with systemic malignancy during an 8-year period, 223 patients had nonactive cancer, 105 patients had active nonmetastatic cancer, and 140 patients had metastasis. During the 6-month follow-up, 122 patients (26.1%) died (nonactive cancer group [7.2%, 16/223], active nonmetastatic cancer group [11.4%, 12/105], and metastatic cancer group [67.1%, 94/140]). Multivariate Cox regression analysis revealed that the presence of metastasis (hazard ratio, 4.527; 95% CI, 2.175-9.422) was independently associated with 6-month mortality. However, the active nonmetastatic cancer group exhibited similar 6-month mortality to the nonactive cancer group (hazard ratio, 0.711; 95% CI, 0.282-1.795). Gastric/esophageal cancer and pancreatic cancer were also independently associated with 6-month mortality (hazard ratio, 2.068 and 2.389, respectively). Conclusions- In stroke patients with active cancer, the presence of metastasis and the cancer type were crucial factors associated with 6-month mortality.
引用
- Yoo J, Nam HS, Kim YD, et al. Short-Term Outcome of Ischemic Stroke Patients With Systemic Malignancy. Stroke. 2019. PMID: 30626288. doi:10.1161/STROKEAHA.118.023044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。